Table 2 Applications of targeting the gut microbiota in the adjuvant therapy of mCRC
From: Role of imbalanced gut microbiota in promoting CRC metastasis: from theory to clinical application
Microbiota intervention | Cancer Therapy | Outcome | Research type | References |
|---|---|---|---|---|
probiotics (oral C.B) | 5-FU and anti-PD-1 | attenuating 5-FU resistance and enhancing anti-PD-1 immunotherapy to inhibit CRC cells proliferation and metastasis | zoopery | [97] |
probiotic mixture | not applicable | reducing angiogenesis and inhibiting CRLM | zoopery | [91] |
probiotic mixture | surgery | changing the gut microenvironment to cause to a decrease in pro-inflammatory cytokines, improving postoperative survival | clinical trail | [98] |
antibiotics (gentamicin and amikacin) | not applicable | inhibiting CRLM in a mouse model | zoopery | [99] |
antibiotics (minocycline) | not applicable | impeding the EMT process in CRC cells to inhibit metastasis | zoopery | [100] |
FMT | anti-PD-1 and anti-VEGF | reducing the size of the tumour to a level suitable for surgical resection and achieving complete pathological remission after surgery | case report | [101] |
HFD | OXP and 5-FU | synergistically enhancing the treatment effect of chemotherapeutics for CRC peritoneal metastasis | zoopery | [102] |